PT027 PhIII asthma trials met primary endpoints
9 September 2021 07:00 BST Fixed-dose combination of albuterol and budesonide (PT027) demonstrated significant benefits for asthma patients in MANDALA and DENALI Phase III trials PT027 significantly reduced the risk of severe exacerbations compared to albuterol in patients with moderate to severe asthma in MANDALA trial when used as a rescue medicine in response to symptoms PT027 significantly improved lung function compared to individual components in mild to moderate asthma in DENALI trial Positive high-level results from the MANDALA and DENALI Phase III trials of PT027 (